Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Forest Laboratories, Inc. et al
Case Number:
1:12-cv-11354
Court:
Nature of Suit:
Other Statutes: False Claims Act
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
May 15, 2017
Forest Wants At Least $6M In Fees After Atty Misconduct
A False Claims Act whistleblower should have to cover more than $6 million in attorneys' fees for Forest Laboratories LLC after building his case on unethically sourced evidence, which led to the suit being dismissed last month, the drugmaker told a Massachusetts federal court Friday.
-
April 28, 2017
Atty Deception Kills Pharma Whistleblower Suit, Judge Rules
A Massachusetts federal judge on Friday sanctioned a whistleblower's attorneys for misconduct in a suit alleging false claims to Medicare by tossing the case, ruling that the complaint wouldn't have survived the dismissal phase had it not relied on unethically sourced evidence.
-
December 06, 2016
Forest Blasts Attys' 'Shameful' Conduct In FCA Suit
Forest Laboratories told a federal judge Tuesday that attorneys for a relator in a False Claims Act suit over the drug Namenda broke patient privacy rules and ethics codes by lying to doctors in a sham marketing study.
-
November 15, 2016
Ex-Forest Sales Rep Defends Counsel In Namenda FCA Suit
A former sales representative blasted Forest Laboratories Inc.’s efforts to shake a False Claims Act suit alleging it illegally marketed Namenda for patients with mild Alzheimer’s by accusing the relator's counsel Milberg LLP of ethical violations, saying Monday that the allegations are baseless and intended to distract from the company’s own discovery violations.
-
July 01, 2014
Forest Labs Slams Ex-Sales Rep's Off-Label Namenda Suit
Forest Laboratories Inc. urged a Massachusetts federal court Monday to toss a False Claims Act suit from a former sales representative accusing it of regularly marketing its dementia drug Namenda for off-label uses such as treating mild Alzheimer's disease to defraud Medicare, saying the complaint fails to state a plausible claim.
-
May 01, 2014
Ex-Rep Says Forest Labs Pushed Off-Label Use Of Namenda
Forest Laboratories Inc. has been hit with a False Claims Act suit by a former sales representative claiming the pharmaceutical giant regularly markets Namenda to treat mild Alzheimer's disease, an off-label indication not approved by the government, according to a complaint unsealed Wednesday in Massachusetts federal court.